Literature DB >> 26968195

Long-Term Blockade of Cocaine Self-Administration and Locomotor Activation in Rats by an Adenoviral Vector-Delivered Cocaine Hydrolase.

John R Smethells1, Natashia Swalve2, Stephen Brimijoin2, Yang Gao2, Robin J Parks2, Adam Greer2, Marilyn E Carroll2.   

Abstract

A promising approach in treating cocaine abuse is to metabolize cocaine in the blood using a mutated butyrylcholinesterase (BChE) that functions as a cocaine hydrolase (CocH). In rats, a helper-dependent adenoviral (hdAD) vector-mediated delivery of CocH abolished ongoing cocaine use and cocaine-primed reinstatement of drug-seeking for several months. This enzyme also metabolizes ghrelin, an effect that may be beneficial in maintaining healthy weights. The effect of a single hdAD-CocH vector injection was examined in rats on measures of anxiety, body weight, cocaine self-administration, and cocaine-induced locomotor activity. To examine anxiety, periadolescent rats were tested in an elevated-plus maze. Weight gain was then examined under four rodent diets. Ten months after CocH-injection, adult rats were trained to self-administer cocaine intravenously and, subsequently, cocaine-induced locomotion was tested. Viral gene transfer produced sustained plasma levels of CocH for over 13 months of testing. CocH-treated rats did not differ from controls in measures of anxiety, and only showed a transient reduction in weight gain during the first 3 weeks postinjection. However, CocH-treated rats were insensitive to cocaine. At 10 months postinjection, none of the CocH-treated rats initiated cocaine self-administration, unlike 90% of the control rats. At 13 months postinjection, CocH-treated rats showed no cocaine-induced locomotion, whereas control rats showed a dose-dependent enhancement of locomotion. CocH vector produced a long-term blockade of the rewarding and behavioral effects of cocaine in rats, emphasizing its role as a promising therapeutic intervention in cocaine abuse.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26968195      PMCID: PMC4851322          DOI: 10.1124/jpet.116.232504

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

1.  Sex differences in the escalation of intravenous cocaine intake following long- or short-access to cocaine self-administration.

Authors:  Megan E Roth; Marilyn E Carroll
Journal:  Pharmacol Biochem Behav       Date:  2004-06       Impact factor: 3.533

2.  Radiometric solvent-partitioning assay for screening cocaine hydrolases and measuring cocaine levels in milligram tissue samples.

Authors:  Stephen Brimijoin; Maryann L Shen; Hong Sun
Journal:  Anal Biochem       Date:  2002-10-15       Impact factor: 3.365

3.  Ghrelin increases anxiety-like behavior and memory retention in rats.

Authors:  Valeria P Carlini; María E Monzón; Mariana M Varas; Andrea B Cragnolini; Helgi B Schiöth; Teresa N Scimonelli; Susana R de Barioglio
Journal:  Biochem Biophys Res Commun       Date:  2002-12-20       Impact factor: 3.575

4.  Food deprivation increases oral and intravenous drug intake in rats.

Authors:  M E Carroll; C P France; R A Meisch
Journal:  Science       Date:  1979-07-20       Impact factor: 47.728

5.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

6.  Plasma butyrylcholinesterase regulates ghrelin to control aggression.

Authors:  Vicky Ping Chen; Yang Gao; Liyi Geng; Robin J Parks; Yuan-Ping Pang; Stephen Brimijoin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

7.  An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats.

Authors:  Yang Gao; Stephen Brimijoin
Journal:  J Pharmacol Exp Ther       Date:  2004-04-20       Impact factor: 4.030

8.  Re-engineering butyrylcholinesterase as a cocaine hydrolase.

Authors:  Hong Sun; Yuan-Ping Pang; Oksana Lockridge; Stephen Brimijoin
Journal:  Mol Pharmacol       Date:  2002-08       Impact factor: 4.436

9.  Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase.

Authors:  Hong Sun; Maryann L Shen; Yuan-Ping Pang; Oksana Lockridge; Stephen Brimijoin
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

10.  Metabolism of cocaine in man.

Authors:  T Inaba; D J Stewart; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

View more
  4 in total

Review 1.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

Review 2.  Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists.

Authors:  Fang Yang; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2019-02-06       Impact factor: 4.530

3.  Reengineering of Albumin-Fused Cocaine Hydrolase CocH1 (TV-1380) to Prolong Its Biological Half-Life.

Authors:  Yingting Cai; Shuo Zhou; Zhenyu Jin; Huimei Wei; Linyue Shang; Jing Deng; Chang-Guo Zhan; Fang Zheng
Journal:  AAPS J       Date:  2019-11-21       Impact factor: 4.009

4.  The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats.

Authors:  Paul R Pentel; Michael D Raleigh; Mark G LeSage; Thomas Thisted; Stephen Horrigan; Zuzana Biesova; Matthew W Kalnik
Journal:  BMC Biotechnol       Date:  2018-07-24       Impact factor: 2.563

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.